Table 3.
The MOFs for co‐immunotherapy with PTT or CDT or RT/RDT
| NPs | Type of MOF | Target | Stimuli‐responsive cargo release | Payload and encapsulation | Applications | Ref. |
|---|---|---|---|---|---|---|
| mFe(SS)/DG | Fe3+‐dithiodiglycolic acid | Homotypic targeting (by coating of cancer cell membrane) | ROS‐responsive (ROS generated by GOx breaks disulfide bonds) | Glucose oxidase (GOx) and DOX | Immunotherapy/CT/CDT | [119] |
| CaP@Fe–MOFs | Fe–TCPP | Tumor cells | pH‐responsive | – | Immunotherapy/CDT | [121] |
| MOF@GOx@MnO2@PEG | MIL‐101(Fe) | Tumor cells | GSH‐responsive | MnO2 and GOx | Immunotherapy/CDT | [120] |
| Dual tailor‐made MOF (HA/IR820@ZIF‐8 and MAN/(R837+1 MT)@ZIF‐8) | ZIF‐8 | Tumor cells (by modification of HA) | pH‐responsive | IR820 | Immunotherapy/PTT | [127] |
| DCs by modification of MAN) | R837 and 1‐methyl‐d‐tryptophan (1 MT) | |||||
| ICG–CpG@MOF | MIL‐101—NH2 | Tumor cells | pH‐responsive | Indocyanine green (ICG) and CpG | Immunotherapy/PTT/PDT | [128] |
| CuCo(O)/GOx@PCNs | Cu/ZIF‐8@ZIF‐67 | Tumor cells | pH‐responsive | Co3O4, Gox, N‐doped carbon nanotube hollow sphere | Immunotherapy/PTT/ starvation | [129] |
| MIL‐100 loaded with MTO and HA as nanoparticles (MMH NPs) | MIL‐100 | Tumor cells (by modification of HA) | pH‐responsive | Mitoxantrone (MTO) | Immunotherapy/PTT/CT | [130] |
| MPSNs@R837 | Zn2+‐porphyrin | Tumor cells | pH‐responsive | Imiquimod (R837) | Immunotherapy/PTT/PDT | [131] |
| ICG@ZIF‐8(Al) NPs | ZIF‐8 | Tumor cells | pH‐responsive | ICG, Al3+ | Immunotherapy/PTT | [132] |
| MIL‐100 NPs with oxaliplatin (OXA) and indocyanine green (ICG) loading and hyaluronic acid (HA) modification (OIMH) NPs | MIL‐100 (Fe) | Tumor cells (by modification of HA) | pH‐responsive | Oxaliplatin (OXA) and ICG | Immunotherapy/PTT/CT | [133] |
| Hf–DBP/TBP | Hf–DBP/TBP | Tumor cells | – | iIDO | Immunotherapy/RT/RDT | [134] |
| Hf6DBA/Hf12DBA | Hf6DBA/Hf12DBA | Tumor cells | – | – | Immunotherapy/RT/RDT | [135] |
| Hf–DBP–Fe | Hf–DBP (doped by Fe3+) | Tumor cells | – | – | Immunotherapy/RT/RDT/CDT | [136] |
| Hf–DBBF–Ir | Hf–DBB–Ir | Tumor cells | – | CpG | Immunotherapy/RT/RDT | [137] |